Innovative Drugs Sold Under the Special Access Programme Can Receive Data Protection in Canada

May 18, 2011

Tags:

Food and Drug Regulatory Intellectual Property Intellectual Property Litigation Litigation and Dispute Resolution Patents Pharmaceuticals

Related Expertise

Related Insights

CUSMA: Canadian patent applications to be eligible for patent term adjustment for unreasonable prosecution delays
Québec Superior Court decision could broaden the federal government’s scope over patented drug pricing
Examining the State of Drug Importation and Drug Pricing
Drug pricing and reimbursement: The role of provinces and hospitals in pharmaceutical pricing
Drug pricing and reimbursement: Federal drug price control

Back